中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

45 records (took 0.052 seconds)

    ANTIBODIES TARGETING CDH19 FOR MELANOMA
    12.
    发明申请
    ANTIBODIES TARGETING CDH19 FOR MELANOMA 有权
    针对MELANOMA的针对CDH19的抗体

    公开(公告)号：US20150322151A1

    公开(公告)日：2015-11-12

    申请号：US14762053

    申请日：2014-01-27

    Applicant: AMGEN INC.

    Inventor： Shouhua Xiao ,  Zheng Pan ,  Dineli Wickramasinghe ,  M. Shawn Jeffries ,  Chadwick Terence King ,  Brian Mingtung Chan

    IPC: C07K16/28 ,  C07K16/30 ,  A61K47/48

    CPC classification number: C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6865 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

    Abstract: The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.

    Abstract translation: 本公开提供了人抗体或其抗原结合片段或包含能够结合目标细胞表面上的人CDH19的人结合结构域或其抗原结合片段的抗体构建体。 本公开涉及编码抗体构建体中包含的抗体或其抗原结合片段的核酸序列，包含核酸序列的载体和用该载体转化或转染的宿主细胞。 此外，本公开涉及制备本公开的抗体构建体的方法，医疗用途或使用抗体构建体的治疗方法和包含抗体或其抗原结合片段或抗体构建体的试剂盒。

    Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
    19.
    发明授权
    Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof 有权
    结合β-klotho，FGF受体及其复合物的人抗原结合蛋白

    公开(公告)号：US09493577B2

    公开(公告)日：2016-11-15

    申请号：US15012939

    申请日：2016-02-02

    Applicant: Amgen Inc.

    Inventor： Shaw-Fen Sylvia Hu ,  Ian Nevin Foltz ,  Chadwick Terence King ,  Yang Li ,  Taruna Arora

    IPC: A61K39/395 ,  C07K16/40 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    Abstract translation: 本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。 在实施方案中，抗原结合蛋白特异性结合（i）β-Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）β-Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法 ，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

Patent Agency Ranking